Video

How USP Is Working to Strengthen Global Supply Chain of Quality-Assured Medicines, Build Manufacturing Capabilities

Emily Kaine, MD, senior VP global health and manufacturing services at US Pharmacopeia (USP), discusses the work USP is engaged in to strengthen the global supply chain of quality-assured medicines and build manufacturing capabilities for new and innovative medicines.

Pharmacy Times interviewed Emily Kaine, MD, senior VP global health and manufacturing services at US Pharmacopeia (USP), on USP’s work to strengthen the global supply chain of quality-assured medicines while building manufacturing capabilities for new and innovative medicines. She also offers insights gleaned from scientific challenges during the drug development and contract manufacturing process that helps to inform the next generation of quality standards for future biomedical technologies and innovations.

The discussion is the eighth in a video series collaboration between Pharmacy Times and USP that highlights USP’s work to support the pharmacist and discussed USP’s perspective on timely and topical issues in the field.

During this video, Kaine discusses what capability building is and how it fits into USP’s mission; what some current developments are in the field of capability building; how capability building supports innovation in the United States; what resources USP has for pharmacists interested in innovation, new technologies, and capability building; and what developments are on the horizon for USP in the new year.

Related Videos
Heart with stethoscope | Image Credit: © DARIKA - stock.adobe.com
Senior Doctor is examining An Asian patient.
Healthcare, pharmacist and woman at counter with medicine or prescription drugs sales at drug store.
Image Credit: © Birdland - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix